Sclerosing of recurrent lymphangioma using OK-432.
The authors present two cases of lymphangioma of the cervicofacial region, treated with a new investigational drug in North America, OK-432 (picibanil), a sclerosing agent intralesionally injected. Both patients had been treated surgically and had recurrence of the tumor. Intralesional injection of OK-432 without aspiration was employed for the first patient, and after aspiration in the second patient. A change in consistency of the tumor, manifested by softening, was followed by marked shrinkage. No complication either locally or systemically has occurred during the follow-up period (10 to 16 months). In both cases, satisfactory results were obtained, resulting in definite reduction in size and improvement in cosmetic appearance. The authors recommend OK-432 intralesional injection for surgically challenging lymphangioma. Their results support those of a recent Japanese study using OK-432 as sclerosing therapy for unresectable lymphangioma.
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004954:Esthetics; D005153:Facial Neoplasms / Q000188:drug therapy / Q000473:pathology; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D015552:Injections, Intralesional; D008202:Lymphangioma / Q000188:drug therapy* / Q000473:pathology; D018191:Lymphangioma, Cystic / Q000188:drug therapy / Q000473:pathology; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D010844:Picibanil / Q000008:administration & dosage / Q000627:therapeutic use*; D012597:Sclerosing Solutions / Q000008:administration & dosage / Q000627:therapeutic use*; D015911:Sclerotherapy; D013396:Suction; D014062:Tongue Neoplasms / Q000188:drug therapy / Q000473:pathology
D000970:Antineoplastic Agents; D012597:Sclerosing Solutions; D010844:Picibanil